You are here: Home ยป Archives for Conference Calls/ Webcasts

Namib Minerals Provides Business Update

How Mine Expansion to 55,000 Tonnes Per Month Targeting H2 2026 Operational Date
Enabling Works Commenced at Redwing; 8–Month Dewatering Program to Begin
Company Outlines $300–400 Million Capital Plan with Non–Dilutive Funding Strategy
Management to Host Business Update Conference Call at 8:00 a.m. Eastern Time

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) — Namib Minerals (“Namib Minerals” or “the Company”), (Nasdaq: NAMM), an established African gold producer with a portfolio of mining and exploration assets in Zimbabwe today provided a business update on its strategic growth initiatives.

“As a publicly traded company, we are committed to transparent communication as we advance our growth strategy,” said Ibrahima Sory Tall, Chief Executive Officer of Namib Minerals. “We are focused on building Namib Minerals into a multi–asset, mid–tier producer through operational optimization at How Mine and the disciplined restart of our Mazowe and Redwing mines. Our engagement of WSP for comprehensive feasibility studies, combined with the commencement of enabling works at Redwing and capacity expansion initiatives at How Mine, demonstrates tangible progress toward our vision. We look forward to updating the investment community on our strategic roadmap and near–term milestones.”

Strategic Growth Update
Since listing on the Nasdaq Stock Exchange in June 2025, Namib Minerals has executed on its strategy to transform from a single–mine operator into a multi–asset gold producer. The Company is advancing a three–pillar growth strategy: operational excellence at How Mine, strategic restarts of Mazowe and Redwing mines, and portfolio diversification through critical minerals exploration.

How Mine Capacity Expansion
As part of its commitment to operational improvement at How Mine, the Company is advancing plans to expand ore milling capacity from 40,500 tonnes per month in 2024 to 55,000 tonnes per month, representing an approximately 36% increase in throughput capacity. The Company is currently working on the procurement of the required equipment and expects this expansion to be operational during the second half of 2026. This capacity expansion will enable the Company to process higher ore volumes and offset the reduction in grade experienced to date in 2025.

Restart Enabling Works
At Redwing, the Company has commenced enabling works. Dewatering is scheduled to commence during the feasibility study phase and is expected to take approximately eight months to reach the targeted mining levels. Dewatering is a critical first step in the restart sequence, allowing the Company to assess underground conditions, refurbish infrastructure, and prepare for a phased production ramp–up. Concurrently, surface–infrastructure and power–supply upgrades will be planned to align with the restart timeline.

At Mazowe, the Company is advancing surface infrastructure work, including power, water, and tailings management systems, alongside detailed engineering studies to optimize the restart sequence and capital efficiency.

WSP Feasibility Studies
Supporting this disciplined approach, the Company has engaged WSP to conduct comprehensive feasibility studies for both Redwing and Mazowe. As announced on November 10, 2025, WSP has been appointed to execute S–K 1300 compliant feasibility studies for both mines simultaneously. Both mines are currently under care and maintenance and require completion of dewatering and resource drilling before redevelopment can commence. The program is expected to be completed over 12 to 18 months and will provide the technical foundation for reserve conversion, permitting, and financing discussions.

Long–Term Strategic Objective
The Company's vision is to build Namib Minerals into a multi–asset, mid–tier gold producer, working toward a strategic goal of ultimately producing 300,000 ounces per year. This represents a long–term corporate objective, not production guidance or a forecast, and is not based on a Preliminary Economic Assessment, Pre–Feasibility Study, or Feasibility Study. Achievement of this objective is contingent upon execution of the Company's long–term strategy, including the successful execution of restart programs and expansion of mines and other exploration and development goals. 

Preliminary Capital Requirements
The Company's preliminary estimate is that the total funding requirement for the expansion program is expected to fall within a range of $300 million to $400 million, with the majority allocated to Redwing Mine. The Company is pursuing a balanced funding mix including structured solutions that minimize dilution and prioritize project debt, strategic partnerships, and internally–generated cash flows to minimize shareholder dilution while supporting growth initiatives. The Company is in dialogue with multiple capital providers to support its growth plans. The Company’s estimated funding requirement amount is preliminary and subject to completion of feasibility studies, final engineering outcomes, market conditions, and equipment costs and other risks and uncertainties, many of which are beyond the Company's control.

Conference Call Information
Interested investors and other parties can listen to a webcast of the live conference call by logging onto the Investor Relations section of the Company's website at https://namibminerals.gcs–web.com/. An archived replay of the webcast will be available on the Company’s website shortly after the event concludes.

Participants may also access the call by dialing (877) 407–9039 for domestic callers or (201) 689–8470 for international callers.

Namib Minerals management will incorporate responses to a selection of shareholders’ frequently asked questions during the webcast. Shareholders are invited to submit questions via the investor relations email address: [email protected]. Please include the hashtag #askNamib in the subject line.

About Namib Minerals
Namib Minerals (NASDAQ: NAMM) is a gold producer, developer and explorer with operations focused in Zimbabwe. Namib Minerals is a significant player in Africa’s mining industry, driving sustainable growth and innovation across the sector. Currently Namib Minerals operates the How Mine, an underground gold mine in Zimbabwe, and aims to restart two assets in Zimbabwe. For additional information, please visit namibminerals.com.

Forward–Looking Statements

This press release includes forward–looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts contained in this update are forward–looking statements. Any statements that refer to estimates or other characterizations of future events or circumstances, including any underlying assumptions, are also forward–looking statements. Forward–looking statements include, without limitation, our management teams’ expectations of funding frameworks and anticipated timelines and costs of the restart of the Mazowe and Redwing Mines, and related assumptions. The forward–looking statements are based on our current expectations and are inherently subject to uncertainties and changes in circumstance and their potential effects and speak only as of the date of such statement. There can be no assurance that future developments will be those that have been anticipated. These forward–looking statements involve a number of risks and uncertainties which include, but are not limited to, (i) market risks, including the price of gold and equipment; (ii) the risk that the Company may not be able to successfully develop its assets as planned, including expanding the How mine and restarting and expanding the Redwing and Mazowe Mines; (iii) the risk that Namib Minerals will be unable to raise additional capital to execute its business plan, which may not be available on acceptable terms or at all; and (iv) political and social risks of operating in Zimbabwe and the DRC. The foregoing list is not exhaustive. You should carefully consider the foregoing factors, any other factors discussed in this press release and the other risks and uncertainties described in the filings we make with Securities and Exchange Commission (the “SEC”). We caution you against placing undue reliance on forward–looking statements, which reflect current beliefs and are based on information currently available as of the date a forward–looking statement is made.

Contacts:
Namib Minerals:
Ibrahima Sory Tall
CEO & Director
Investor Relations:
[email protected]


GLOBENEWSWIRE (Distribution ID 9591191)

Namib Minerals Schedules Business Update Call

NEW YORK, Nov. 20, 2025 (GLOBE NEWSWIRE) — Namib Minerals (“Namib Minerals” or “the Company”), (Nasdaq: NAMM), an established African gold producer with a portfolio of mining and exploration assets in Zimbabwe and the Democratic Republic of Congo, today announced that management will host a webcast and conference call to provide a business update at 8:00 AM ET on Monday, November 24, 2025.

Interested investors and other parties can listen to a webcast of the live conference call by logging onto the Investor Relations section of the Company's website at https://namibminerals.gcs–web.com/. An archived replay of the webcast will be available shortly after the event concludes.

Participants may also access the call by dialing (877) 407–9039 for domestic callers or (201) 689–8470 for international callers.

Namib Minerals management will incorporate responses to a selection of shareholders’ frequently asked questions during the webcast. Shareholders are invited to submit questions via the investor relations email address: [email protected]. Please include the hashtag #askNamib in the subject line.

About Namib Minerals

Namib Minerals (NASDAQ: NAMM) is a gold producer, developer and explorer with operations focused in Zimbabwe. Namib Minerals is a significant player in Africa’s mining industry, driving sustainable growth and innovation across the sector. Currently Namib Minerals operates the How Mine, an underground gold mine in Zimbabwe, and aims to restart two assets in Zimbabwe, with additional exploration assets in the DRC. For additional information, please visit namibminerals.com.

Contacts:
Namib Minerals:
Ibrahima Sory Tall
CEO & Director
Investor Relations:
[email protected]


GLOBENEWSWIRE (Distribution ID 9580064)

NeOnc Technologies (Nasdaq: NTHI) to Host Investor Conference Call to Present Data Updates from Ongoing NEO100-1 Phase 1/2a Clinical Trial and Compassionate Use Program

CALABASAS, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) — NeOnc Technologies Holdings, Inc. (NTHI) (“NeOnc” or the “Company”), a clinical–stage biopharmaceutical company developing novel brain–penetrant therapeutics for patients with malignant brain tumors and central nervous system (CNS) disorders, today announced that it will host an investor conference call and webcast on Wednesday, November 12, 2025, at 6:00 a.m. Pacific Time / 9:00 a.m. Eastern Time (prior to market open).

During the call, members of the NTHI management team and independent members of the company’s Scientific Advisory Board (SAB) will present data updates from the Company’s ongoing Phase 1/2a NEO100–1 clinical trial and compassionate use program, evaluating intranasal delivery of NEO100 (high–purity perillyl alcohol) in patients with recurrent high grade malignant glioma.

The discussion will highlight MRI–based radiographic response data, progression–free survival (PFS), and overall survival (OS) trends observed to date, providing important insights into long–term clinical outcomes for patients treated with NEO100.

Featured Participants:

  • Dr. Henry S. Friedman, MD – Deputy Director, Preston Robert Tisch Brain Tumor Center, Duke University; Independent Member, NTHI Scientific Advisory Board
  • Dr. Alexander Miller, MD – Chief Neuro–oncology, Brain Tumor Program, NYU Langone Health; Independent Member, NTHI Scientific Advisory Board
  • NTHI Management Team:
    • Amir Heshmatpour – Chief Executive Officer, Executive Chairman and President
    • Dr. Thomas C. Chen, MD, PhD – Chief Medical Officer and Chief Scientific Officer
    • Dr. Josh Neman, PhD – Chief Clinical Officer
    • Keith Garnett – Chief Financial Officer

Conference Call Details:

  • Date: Wednesday, November 12, 2025
  • Time: 6:00 a.m. PT / 9:00 a.m. ET
  • Webcast: A live webcast can be accessed by visiting https://investors.neonc.com

ABOUT NEONC TECHNOLOGIES HOLDINGS, INC.
NeOnc Technologies Holdings, Inc. is a clinical–stage life sciences company focused on the development and commercialization of central nervous system therapeutics that are designed to address the persistent challenges in overcoming the blood–brain barrier. The company’s NEO™ drug development platform has produced a portfolio of novel drug candidates and delivery methods with patent protections extending to 2038. These proprietary chemotherapy agents have demonstrated positive effects in laboratory tests on various types of cancers and in clinical trials treating malignant gliomas. NeOnc’s NEO100™ and NEO212™ therapeutics are in Phase II human clinical trials and are advancing under FDA Fast–Track and Investigational New Drug (IND) status. The company has exclusively licensed an extensive worldwide patent portfolio from the University of Southern California consisting of issued patents and pending applications related to NEO100, NEO212, and other products from the NeOnc patent family for multiple uses, including oncological and neurological conditions.

For more about NeOnc and its pioneering technology, visit neonc.com.

Important Cautions Regarding Forward–Looking Statements
This press release contains “forward–looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward–looking statements can be identified by terminology such as “may,” “will,” “should,” “intend,” “expect,” “plan,” “budget,” “forecast,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue,” “evaluating,” or similar words. Statements that contain these words should be read carefully, as they discuss our future expectations, projections of future results of operations or financial condition, or other forward–looking information.

Examples of forward–looking statements include, among others, statements regarding whether a definitive agreement will be reached with Quazar. These statements reflect our current expectations based on information available at this time, but future events may differ materially from those anticipated.

The “Risk Factors” section of our most recent Annual Report on Form 10–K filed with the Securities and Exchange Commission, along with other cautionary language in that report or in our subsequent filings, outlines important risks and uncertainties. These may cause our actual results to differ materially from the forward–looking statements herein, including but not limited to the failure to finalize the agreement with Quazar, modifications to its terms, or alternative uses of proceeds.

We assume no obligation to revise or update any forward–looking statements, whether as a result of new information, future developments, or otherwise, except as required by applicable securities laws and regulations.

“NEO100” and NEO “212” are registered trademarks of NeOnc Technologies Holdings, Inc.

Company Contact:
[email protected]

Investor Contact:
James Carbonara
Hayden IR
(646)–755–7412
[email protected]


GLOBENEWSWIRE (Distribution ID 9571142)

Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences

  • Osteoporosis Program: Phase 2 analysis exploring the dual actions of oral PTH(1–34) tablet treatment, EB613 on trabecular and cortical bone, and Next–Gen EB613 PK/PD data slated for oral and poster presentations at ASBMR
  • Short Bowel Syndome and Rare GI Disorders: PK/PD of oral GLP–2 tablet candidate poster presentation at ESPEN
  • Corporate Overview at H.C. Wainwright Investor Conference

JERUSALEM, Aug. 28, 2025 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and proteins replacement therapies, today announced that the Company will present data across three key programs during September 2025. Details on the presentations are available below:

American Society for Bone and Mineral Research (ASBMR) 2025 Annual Meeting:
Oral Presentation – Dr. Rachel B. Wagman

  • Title: Effects of EB613 Tablets [Oral PTH(1–34)] on Trabecular and Cortical Bone Using 3D–DXA: Results from Phase 2 Study (1014)
  • Time: Friday, September 5, 2025, 11:45 AM
  • Location: General Session Room, 6BC (6th Floor, Seattle Convention Center)

EB613 is being developed as the first, once–daily oral anabolic (bone forming) tablet treatment for postmenopausal women with osteoporosis. A placebo–controlled Phase 2 study in 161 post–menopausal women produced a rapid onset of action with increases in BMD at both cortical bone (femoral neck and hip region) and cancellous bone (spine). Based on a July 2025 alignment with FDA, Entera is planning a global Phase 3 registration study of EB613 in women with osteoporosis.

Poster Presentation – Next–Gen EB613

  • Title: Advancing Oral Anabolic Treatments for Osteoporosis: Pre–Clinical Data for Next–Gen EB613 Tablet Utilizing N–Tab™ Proprietary Technology (581)
  • Time: Sunday, September 7, 2025, 2:00 PM – 3:30 PM
  • Location: Discovery Hall, Hall 4B (4th Floor, Seattle Convention Center)

47th European Society for Clinical Nutrition & Metabolism (ESPEN) Congress

Poster Presentation – GLP–2 Short Bowel Syndrome:

  • Title: A First–in–Class Oral GLP–2 Analog for Treatment of Short Bowel Syndrome
  • Time: Saturday, September 13, 2025, 3:30 PM – 4:00 PM
  • Location: Forum Hall Foyer 3, Prague, Czech Republic

The oral GLP–2 tablet program combines a proprietary long acting GLP–2 agonist developed by OPKO Health with Entera's proprietary N–Tab™ technology for patients suffering from short bowel syndrome and additional disorders involving gastrointestinal mucosal inflammation and nutrient malabsorption. Currently, the only approved GLP–2 agonist requires daily subcutaneous injections.

H.C. Wainwright Conference

Entera’s Chief Executive Officer Miranda Toledano will present at the H.C. Wainwright 27th Annual Global Investment Conference. The virtual presentation will be available on Friday, September 5, 2025 at 7:00 AM ET at:

https://journey.ct.events/view/0f59c59b–da4e–4dc2–a865–4f1883eca26f

About Entera Bio

Entera is a clinical stage company focused on developing oral peptide and protein replacement therapies for significant unmet medical needs where an oral tablet form holds the potential to transform the standard of care. The Company leverages on a disruptive and proprietary technology platform (N–Tab™) and a pipeline of first–in–class oral peptide programs targeting PTH(1–34), GLP–1 and GLP–2. The Company’s most advanced product candidate, EB613 (oral PTH(1–34)teriparatide), is being developed as the first oral, osteoanabolic (bone building) once–daily tablet treatment for post–menopausal women with low BMD and high–risk osteoporosis. A placebo controlled, dose ranging Phase 2 study of EB613 tablets (n= 161) met primary (PD/bone turnover biomarker) and secondary endpoints (BMD). Entera is preparing to initiate a Phase 3 registrational study for EB613 with alignment from FDA on the use of BMD as its primary endpoint. The EB612 program is being developed as the first oral PTH(1–34) tablet peptide replacement therapy for hypoparathyroidism. Entera is also developing the first oral oxyntomodulin, a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity; and first oral GLP–2 peptide tablet as an injection–free alternative for patients suffering from rare malabsorption conditions such as short bowel syndrome in collaboration with OPKO Health. For more information on Entera Bio, visit www.enterabio.com or follow us on LinkedIn, Twitter, Facebook, Instagram.

Cautionary Statement Regarding Forward Looking Statements

Various statements in this presentation are “forward–looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements (other than statements of historical facts) in this presentation regarding our prospects, plans, financial position, business strategy and expected financial and operational results may constitute forward–looking statements. Words such as, but not limited to, “anticipate,” “believe,” “can,” “could,” “expect,” “estimate,” “design,” “goal,” “intend,” “may,” “might,” “objective,” “plan,” “predict,” “project,” “target,” “likely,” “should,” “will,” and “would,” or the negative of these terms and similar expressions or words, identify forward–looking statements. Forward–looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Forward–looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Important factors that could cause actual results to differ materially from those reflected in Entera’s and OPKO’s forward–looking statements include, among others: changes in the interpretation of clinical data; results of our clinical trials; the FDA’s interpretation and review of our results from and analysis of our clinical trials; unexpected changes in our ongoing and planned preclinical development and clinical trials, the timing of and our ability to make regulatory filings and obtain and maintain regulatory approvals for our product candidates; the potential disruption and delay of manufacturing supply chains; loss of available workforce resources, whether by Entera, OPKO or their respective collaboration and laboratory partners; impacts to research and development or clinical activities that Entera or OPKO may be contractually obligated to provide; overall regulatory timelines; the size and growth of the potential markets for our product candidates; the scope, progress and costs of developing our product candidates; the parties’ reliance on third parties to conduct clinical trials; Entera’s and OPKO’s expectations regarding licensing, business transactions, including OPKO’s development efforts should Entera opt–out, and strategic collaborations; Entera’s operation as a development stage company with limited operating history; Entera’s ability to continue as a going concern absent access to sources of liquidity; Entera’s ability to comply with Nasdaq’s minimum listing standards and other matters related to compliance with the requirements of being a public company in the United States; Entera’s and OPKO’s intellectual property positions and their ability to protect their respective intellectual property; and other factors that are described in the “Cautionary Statements Regarding Forward–Looking Statements,” “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of each of Entera’s and OPKO’s most recent Annual Reports on Form 10–K filed with the SEC, as well as the companies’ respective subsequently filed Quarterly Reports on Form 10–Q and Current Reports on Form 8–K. There can be no assurance that the actual results or developments anticipated by Entera and OPKO will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Entera or OPKO, as applicable. Therefore, no assurance can be given that the outcomes stated or implied in such forward–looking statements and estimates will be achieved. Entera and OPKO caution investors not to rely on the forward–looking statements made in this press release. The information in this press release is provided only as of the date of this press release, and neither Entera nor OPKO undertakes any obligation to update or revise publicly any forward–looking statements, whether as a result of new information, future events or otherwise, except to the extent required by law.


GLOBENEWSWIRE (Distribution ID 9519749)

Zoom to Release Financial Results for the Second Quarter of Fiscal Year 2026

SAN JOSE, Calif., July 31, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the second quarter of fiscal year 2026 on Thursday, August 21, 2025, after the market closes.

A live Zoom Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.com. A replay will be available approximately two hours after the conclusion of the live event.

About Zoom
Zoom’s mission is to provide an AI–first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Public Relations
Colleen Rodriguez
Head of Global PR for Zoom
[email protected]

Investor Relations
Charles Eveslage
Head of Investor Relations for Zoom
[email protected]


GLOBENEWSWIRE (Distribution ID 9503211)

Zoom to Release Financial Results for the Second Quarter of Fiscal Year 2026

SAN JOSE, Calif., July 31, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the second quarter of fiscal year 2026 on Thursday, August 21, 2025, after the market closes.

A live Zoom Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.com. A replay will be available approximately two hours after the conclusion of the live event.

About Zoom
Zoom’s mission is to provide an AI–first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Public Relations
Colleen Rodriguez
Head of Global PR for Zoom
[email protected]

Investor Relations
Charles Eveslage
Head of Investor Relations for Zoom
[email protected]


GLOBENEWSWIRE (Distribution ID 9503211)

Zoom to Release Financial Results for the First Quarter of Fiscal Year 2026

SAN JOSE, Calif., May 01, 2025 (GLOBE NEWSWIRE) — Zoom Communications, Inc. (NASDAQ: ZM) today announced it will release its financial results for the first quarter of fiscal year 2026 on Wednesday, May 21, 2025, after the market closes.

A live Zoom Webinar of the event can be accessed at 2:00 pm PT / 5:00 pm ET through Zoom’s investor relations website at https://investors.zoom.com. A replay will be available approximately two hours after the conclusion of the live event.

About Zoom
Zoom’s mission is to provide an AI–first work platform for human connection. Reimagine teamwork with Zoom Workplace — Zoom’s open collaboration platform with AI Companion empowers teams to be more productive. Together with Zoom Workplace, Zoom’s Business Services for sales, marketing, and customer experience teams, including Zoom Contact Center, strengthen customer relationships throughout the customer lifecycle. Founded in 2011, Zoom is publicly traded (NASDAQ:ZM) and headquartered in San Jose, California. Get more information at zoom.com.

Public Relations
Colleen Rodriguez
Head of Global PR for Zoom
[email protected]

Investor Relations
Charles Eveslage
Head of Investor Relations for Zoom
[email protected]


GLOBENEWSWIRE (Distribution ID 9442957)

Synchronoss Technologies annonce la date de la conférence téléphonique qui fera le point sur ses résultats du quatrième trimestre et son exercice 2024

BRIDGEWATER, New Jersey, 26 févr. 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. (« Synchronoss » ou la « Société ») (NASDAQ : SNCR), un innovateur et leader mondial des plateformes de cloud personnel, organisera une conférence téléphonique le mardi 11 mars 2025 à 16 h 30, heure de l’Est (13 h 30, heure du Pacifique) pour faire le point sur ses résultats financiers du quatrième trimestre et sur l’ensemble de son exercice clos le 31 décembre 2024. Avant cette conférence téléphonique, les résultats financiers seront publiés dans un communiqué de presse.

La direction de Synchronoss animera la présentation, qui se poursuivra par une session de questions–réponses.

Date : mardi 11 mars 2025
Heure : 16 h 30, heure de l’Est (13 h 30, heure du Pacifique)
Numéro de téléphone : 877–451–6152 (national) ou 201–389–0879 (international)
Identifiant de la conférence : 13751475

La conférence téléphonique sera retransmise en direct ici et sur la page « Relations avec les investisseurs » du site Internet de Synchronoss.

À propos de Synchronoss
Synchronoss Technologies (Nasdaq : SNCR), un leader mondial de solutions de cloud personnalisées, permet aux prestataires de services d’établir des connexions sécurisées et pertinentes avec leurs abonnés. Notre plateforme SaaS Cloud simplifie les processus d’intégration des clients et favorise l’engagement des abonnés, avec pour résultat une amélioration des flux de revenus, une réduction des dépenses et une accélération de la mise sur le marché. Des millions d’abonnés font confiance à Synchronoss pour préserver leurs souvenirs les plus chers et les contenus numériques les plus importants. Découvrez comment nos solutions axées sur le cloud redéfinissent la manière dont vous vous connectez à votre monde numérique sur www.synchronoss.com.

Contact pour les relations avec les médias :
Domenick Cilea
Springboard
[email protected]

Contact pour les relations avec les investisseurs :
Ryan Gardella
ICR pour Synchronoss
[email protected]


GLOBENEWSWIRE (Distribution ID 9385437)

Synchronoss Technologies Anuncia a Data da Chamada de Resultados do Quarto Trimestre e do Ano de 2024

BRIDGEWATER, N.J., Feb. 26, 2025 (GLOBE NEWSWIRE) — A Synchronoss Technologies, Inc. (“Synchronoss” ou a “Empresa”) (Nasdaq: SNCR), líder global e inovadora em plataformas de Nuvem Pessoal, fará uma teleconferência na terça–feira, 11 de março de 2025, às 16h30, horário do leste dos EUA (13h30, horário do Pacífico), para discutir seus resultados financeiros do quarto trimestre e do ano encerrado em 31 de dezembro de 2024. Os resultados financeiros serão divulgados em um comunicado para a imprensa antes da chamada.

A gerência da Synchronoss fará a apresentação que será seguida de uma sessão de perguntas e respostas.

Data: Terça–feira, 11 de março de 2025
Hora: 16h30 Horário do Leste dos EUA (13h30 Horário do Pacífico)
Número a chamar: 877–451–6152 (nacional) ou 201–389–0879 (internacional)
ID da Conferência: 13751475

A teleconferência será transmitida ao vivo aqui e através da seção de Relações com Investidores do site da Synchronoss.

Sobre a Synchronoss
A Synchronoss Technologies(Nasdaq: SNCR), líder global em soluções pessoais de Nuvem, capacita os provedores de serviços a estabelecer conexões seguras e significativas com seus assinantes. Nossa plataforma SaaS Cloud simplifica os processos de integração e promove o envolvimento dos assinantes, resultando em fluxos de receita aprimorados, despesas reduzidas e tempo de comercialização mais rápido. Milhões de assinantes confiam na Synchronoss para proteger suas memórias mais queridas e conteúdo digital importante. Explore como as nossas soluções focadas na Nuvem redefinem a forma da conexão digital com seu mundo digital em www.synchronoss.com.

Contato de Relações com a Mídia:
Domenick Cilea
Springboard
[email protected]

Contato de Relações com Investidores:
Ryan Gardella
ICR em nome da Synchronoss
[email protected]


GLOBENEWSWIRE (Distribution ID 9385437)

Synchronoss Technologies kündigt Telefonkonferenz für das vierte Quartal und das gesamte Geschäftsjahr 2024 an

BRIDGEWATER, New Jersey, Feb. 26, 2025 (GLOBE NEWSWIRE) — Synchronoss Technologies, Inc. („Synchronoss“ oder das „Unternehmen“) (Nasdaq: SNCR), ein weltweit führender Anbieter und Innovator im Bereich persönlicher Cloud–Plattformen, wird am Dienstag, den 11. März 2025, um 16:30 Uhr (EST) eine Telefonkonferenz abhalten (13:30 Uhr pazifische Zeit), um die finanziellen Ergebnisse für das vierte Quartal und das gesamte Geschäftsjahr zum 31. Dezember 2024 zu besprechen. Die Finanzergebnisse werden vor der Telefonkonferenz in einer Pressemitteilung veröffentlicht.

Die Geschäftsführung von Synchronoss wird die Präsentation mit anschließender Frage–Antwort–Runde vortragen.

Datum: Dienstag, 11. März 2025
Uhrzeit: 16:30 Uhr EST (13:30 Uhr pazifische Zeit)
Einwahlnummer: 877–451–6152 (Inland) oder 201–389–0879 (Ausland)
Konferenz–ID: 13751475

Die Telefonkonferenz wird live hier und im Bereich Investor Relations auf der Website von Synchronoss übertragen.

Über Synchronoss
Synchronoss Technologies (Nasdaq: SNCR), ein weltweit führender Anbieter von persönlichen Cloud–Lösungen, ermöglicht es Dienstanbietern, sichere und sinnvolle Verbindungen zu ihren Abonnenten herzustellen. Unsere SaaS–Cloud–Plattform vereinfacht die Onboarding–Prozesse und fördert die Kundenbindung, was zu verbesserten Umsatzströmen, geringeren Kosten und einer schnelleren Markteinführung führt. Millionen von Abonnenten vertrauen darauf, dass Synchronoss ihre wertvollsten Erinnerungen und wichtigen digitalen Inhalte schützt. Erfahren Sie unter www.synchronoss.com, wie unsere Cloud–Lösungen die Art und Weise, wie Sie sich mit Ihrer digitalen Welt verbinden, neu definieren.

Medienkontakt:
Domenick Cilea
Springboard
[email protected]

Investorenkontakt:
Ryan Gardella
ICR für Synchronoss
[email protected]


GLOBENEWSWIRE (Distribution ID 9385437)